Furthermore, SSZ is currently being explored therapeutically as a treatment in patients with cancer, though this is based on its ability to reduce pain via efflux of glutamate due to its inhibitory effect on the cysteine/glutamate antiporter SLC7A11 (Clinical Trial NCT number NCT03847311). This evidence concerns the gene SLC7A11 and cancer.